Oxford Biomedica Reports First Half Revenue Growth of 10%
Oxford Biomedica (OTCMKTS: OXBDF) reported first-half revenue growth of 10% to £80.2 million, driven by continued demand for its gene therapy manufacturing services. The company reiterated its guidance for FY 2026, forecasting constant currency revenue in the range of £180M–£200M and EBITDA margins expected to be mid-single-digit percentage excluding one-off costs or low-single-digit on a reported basis. Looking ahead, Oxford Biomedica anticipates FY 2027 revenue growth between 25% and 30% year-over-year. The results reflect the company's ongoing expansion in its core gene therapy business as it supports multiple clinical programs across various therapeutic areas.
